Ignite Creation Date:
2025-12-24 @ 11:04 PM
Ignite Modification Date:
2026-01-01 @ 10:48 PM
Study NCT ID:
NCT04910269
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2021-06-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C084715', 'term': 'HIV hyperimmune globulin'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 820}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2021-08-06', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2026-08-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-11', 'studyFirstSubmitDate': '2021-06-01', 'studyFirstSubmitQcDate': '2021-06-01', 'lastUpdatePostDateStruct': {'date': '2025-12-17', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2021-06-02', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-08-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Clinical Status', 'timeFrame': '7 days', 'description': 'The primary outcome is to compare the safety and efficacy of a single infusion of hIVIG versus placebo on clinical status after seven days. Outcome will be reported as the percent of participants who fall into each of 5 clinical status categories as defined below.\n\n1. Asymptomatic and no limitations in usual activity due to COVID-19\n2. Mild COVID-19 illness or minor limitations to usual activity\n3. Moderate COVID-19 illness and with major limitations to usual activity\n4. Severe COVID-19 or serious disease manifestation from COVID-19\n5. Critical illness from COVID-19 or Death'}], 'secondaryOutcomes': [{'measure': 'All-cause hospitalization or death through 28 days.', 'timeFrame': '28 days', 'description': 'Outcome reported as the percent of participants who are hospitalized or who expire for any reason by day 28 post treatment.'}, {'measure': 'All-cause mortality through 28 days.', 'timeFrame': '28 days', 'description': 'Outcome reported as the percent of participants who expire for any reason by day 28 post treatment.'}, {'measure': 'Significant Disease Progression', 'timeFrame': '28 days', 'description': 'Outcome is reported as the number of participants with significant disease progression through 28 days, which is defined by fulfilling criteria for category 4 or 5 on the ordinal scale using a time to event analysis.'}, {'measure': 'Ordinal Scale Distribution', 'timeFrame': '4, 14, 28 days', 'description': 'Outcome will be reported as the percent of participants who fall into each of 5 clinical status categories as defined below at days 4, 14, and 28 following treatment.\n\n1. Asymptomatic and no limitations in usual activity due to COVID-19\n2. Mild COVID-19 illness or minor limitations to usual activity\n3. Moderate COVID-19 illness and with major limitations to usual activity\n4. Severe COVID-19 or serious disease manifestation from COVID-19\n5. Critical illness from COVID-19 or Death'}, {'measure': 'Disease Progression Through 7 Days', 'timeFrame': '7 days', 'description': 'Outcome is reported as the proportion of participants with any disease progression at Day 7, using a sliding dichotomous scale progression defined by a categorization on the ordinal scale that is worse than the status at entry.'}, {'measure': 'Significant Disease Progression Through 7 Days', 'timeFrame': '7 days', 'description': 'Outcome is reported as the proportion of participants who progress to categories 3-5 on the clinical ordinal scale at Day 7 among participants in categories 1 or 2 of the ordinal scale at entry.'}, {'measure': 'Disease Progression at Follow-up', 'timeFrame': '7, 14, 28 days', 'description': 'Outcome is reported as the percent of participants who experience severe disease progression during follow-up, defined by the worst health status achieved on the clinical ordinal scale at any point by Day 7, 14, and 28.'}, {'measure': 'Activity Limitations at Follow-up', 'timeFrame': '7, 14, 28 days', 'description': 'Outcome is reported as the percent of participants who attain their pre-COVID health status without limitations in usual activity (defined as category 1 on the ordinal scale) at Day 7, 14, and 28.'}, {'measure': 'Change in Viral Burden from Serum Antigen', 'timeFrame': '7 days', 'description': 'Outcome is reported as the change between Day 0 and Day 7 in viral burden as determined by serum antigen levels from nasal and saliva specimens.'}, {'measure': 'Change in Viral Burden from PCR', 'timeFrame': '7 days', 'description': 'Outcome is reported as the change between Day 0 and Day 7 in viral burden as determined by polymerase chain reaction (PCR) from nasal and saliva specimens.'}, {'measure': 'Change in SARS-CoV-2 Antibody Concentration', 'timeFrame': '7 days', 'description': 'Outcome is reported as the change in SARS-CoV-2 antibody levels between Day 0 and Day 7, including subclasses and neutralizing titers.'}, {'measure': 'Healthcare Utilization at Follow-up', 'timeFrame': '28 days', 'description': 'Outcome is reported as the percent of participants who had health care engagement for the purposes of medical evaluation and/or management of COVID-19 illness (e.g., via telehealth, clinic, urgent care, emergency room, or hospitalization) at 28 days follow-up.'}, {'measure': 'Worst Status Through 28 Days', 'timeFrame': '28 days', 'description': 'Outcome is reported as the number of participants who experience each of the following categories as their worst respiratory status through 28 days, including: a) no respiratory symptoms, b) upper respiratory symptoms, c) lower respiratory symptoms without hypoxia, c) hypoxia requiring conventional oxygen supplementation by nasal canula, d) respiratory failure requiring high-flow oxygen delivery device or non-invasive ventilation, or e) respiratory failure requiring mechanical ventilation or extra-corporeal membrane oxygenation (ECMO).'}, {'measure': 'Hypoxemia Through Day 7', 'timeFrame': '7 days', 'description': 'Outcome is reported as the mean oxygen saturation (percentage) level in each group at 7 days.'}, {'measure': 'Additional COVID-19 Treatment', 'timeFrame': '28 days', 'description': 'Outcome is reported as the number of patients starting other treatments targeting COVID-19 through 28 days post treatment.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['immunotherapy', 'hIVIG', 'early treatment'], 'conditions': ['COVID', 'SARS-CoV2 Infection', 'Covid19']}, 'referencesModule': {'references': [{'pmid': '36216961', 'type': 'DERIVED', 'citation': 'Jha A, Barker D, Lew J, Manoharan V, van Kessel J, Haupt R, Toth D, Frieman M, Falzarano D, Kodihalli S. Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection. Sci Rep. 2022 Oct 10;12(1):16956. doi: 10.1038/s41598-022-21223-2.'}]}, 'descriptionModule': {'briefSummary': "The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed severe acute respiratory syndrome - coronavirus 2 (SARS-CoV2) infection who do not require hospitalization. The primary endpoint of this double-blind randomized trial is a five-category ordinal outcome that assesses the participant's clinical status seven days after the infusion of hIVIG or placebo.\n\n1. Asymptomatic and no limitations in usual activity due to COVID-19\n2. Mild COVID-19 illness or minor limitations to usual activity\n3. Moderate COVID-19 illness and with major limitations to usual activity\n4. Severe COVID-19 or serious disease manifestation from COVID-19\n5. Critical illness from COVID-19 or Death\n\nTwo strata of participants will be identified for analysis purposes. Stratum 2 will be participants who receive direct-acting antivirals (DAAs) or other anti-SARS-CoV2 agents that are approved/available and recommended for use as part of standard of care (SOC), estimated to be about 20% of participants. Stratum 1 will be participants who do not receive this agents, estimated to be about 80% of participants.", 'detailedDescription': 'The primary objective will be addressed by testing two hypotheses aimed at assessing whether hIVIG + standard of care (SOC) is superior to placebo + SOC for the primary ordinal endpoint at Day 7. These hypotheses will be tested for the following two groups: a) among all randomized participants (stratum 1 and 2), and b) among only participants enrolled in stratum 1. For the primary analysis, overall type 1 error will be controlled at 5% by using a 2-sided significance level of 0.035 for each hypothesis. This significance level was obtained using the correlation between the test statistics for the proportional log odds ratio for all randomized participants and for this log odds ratio for those in stratum 1. This correlation was determined to be 0.895. With this approach hIVIG will be considered superior to placebo if either of the two hypotheses is rejected.\n\nParticipants will be randomized to a single infusion of an hIVIG product or placebo in a 1:1 allocation. Randomization will be stratified by study site pharmacy and the two SOC strata.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Clinical risk based on age ≥ 55 years or an adult (age ≥ 18 years) with an immunosuppressed condition.\n* Positive test for SARS-CoV-2 within ≤5 days (if \\>1 test, the first positive is within ≤5 days). Tests may include an institutional-based nucleic acid amplification test (NAAT), or any protocol-approved rapid test.\n* Within ≤5 days from symptom onset, if symptomatic from current SARS-CoV-2 infection.\n* Agrees to not participate in another clinical trial for the treatment or management of SARS-CoV-2 infection through Day 7, or until hospitalized or significant disease progression if prior to Day 7 (defined by ordinal category 4 or 5).\n* Participant provides written informed consent prior to study procedures, and understands and agrees to adhere to planned study procedures through Day 28.\n\nOngoing immunosuppressive condition or immunosuppressive treatment, includes:\n\n1. Steroids equivalent to prednisone \\> 10 mg/day for at least the last 28 days\n2. Rheumatologic or autoimmune disorder treated with a biologic or non-biologic immunosuppressive therapy\n3. Antirejection medicine after solid organ or stem cell transplantation\n4. Cancer treatment with systemic chemotherapy, biologic and/or cell-based therapy in the last 12 months\n5. Primary or acquired severe B- or T-lymphocyte immune dysfunction\n6. HIV infection\n7. Splenectomy or functional asplenia\n\nExclusion Criteria:\n\n* Asymptomatic and had prior symptoms from the current infection that have now resolved (for \\>24 hours).\n* Asymptomatic and has received a vaccination for COVID-19 (≥1 dose).\n* Undergoing evaluation for possible admission to hospital for medical management (this does not include evaluation of possible hospitalization for public health purposes).\n* Evidence of pneumonia and/or hypoxia due to COVID-19 (NOTE: chest imaging is not required, but if available it should not show new infiltrates suggestive of pneumonia; hypoxia is defined by new oxygen supplementation or increase above pre-illness level).\n* Prior receipt of immunoglobulin product or passive immune therapy for SARS-CoV-2 in the past 90 days (i.e., convalescent plasma, SARS-CoV-2 monoclonal antibodies, or any IVIG).\n* Any of the following thrombotic or procoagulant conditions or disorders:\n\n 1. acute coronary syndrome, cerebrovascular syndrome, pulmonary embolism, or deep venous thrombosis within 28 days of randomization.\n 2. prothrombin gene mutation 20210, homozygous Factor V Leiden mutations, antiphospholipid syndrome, or a deficiency in antithrombin III, protein C, or protein S.\n* History of hypersensitivity to blood, plasma or IVIG excipients.\n* Known immunoglobulin A (IgA) deficiency or anti-IgA antibodies.\n* In the opinion of the investigator, any condition for which participation would not be in the best interest of the participant or that could prevent or confound protocol assessments.'}, 'identificationModule': {'nctId': 'NCT04910269', 'acronym': 'OTAC', 'briefTitle': 'Outpatient Treatment With Anti-Coronavirus Immunoglobulin', 'organization': {'class': 'OTHER', 'fullName': 'University of Minnesota'}, 'officialTitle': 'An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19', 'orgStudyIdInfo': {'id': 'INSIGHT12'}, 'secondaryIdInfos': [{'id': '2021-001663-24', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment Group', 'description': 'Participants in this group will receive the investigational treatment in addition to standard of care.', 'interventionNames': ['Biological: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo Group', 'description': 'Participants in this group will receive a placebo in addition to standard of care.', 'interventionNames': ['Other: Placebo']}], 'interventions': [{'name': 'Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)', 'type': 'BIOLOGICAL', 'description': 'The hIVIG product is administered as a single dose of 3.5 grams, or 35 milliliter at a concentration of 0.1 grams/milliliter.', 'armGroupLabels': ['Treatment Group']}, {'name': 'Placebo', 'type': 'OTHER', 'description': 'Infusion of 35 milliliters standard isotonic saline', 'armGroupLabels': ['Placebo Group']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85723', 'city': 'Tucson', 'state': 'Arizona', 'status': 'TERMINATED', 'country': 'United States', 'facility': 'Southern Arizona VA Healthcare System (074-009)', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '95655', 'city': 'Mather', 'state': 'California', 'status': 'TERMINATED', 'country': 'United States', 'facility': 'VA Northern California Health Care System (074-023)', 'geoPoint': {'lat': 37.88215, 'lon': -119.85573}}, {'zip': '94305', 'city': 'Palo Alto', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Hennepin ICC', 'role': 'CONTACT', 'email': 'otachenn@insight-trials.org'}, {'name': 'Aruna Subramanian', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Stanford University Hospital & Clinics (Site 203-003)', 'geoPoint': {'lat': 37.44188, 'lon': -122.14302}}, {'zip': '94121', 'city': 'San Francisco', 'state': 'California', 'status': 'TERMINATED', 'country': 'United States', 'facility': 'San Francisco VAMC (Site 074-002)', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'status': 'TERMINATED', 'country': 'United States', 'facility': 'Rocky Mountain Regional VA Medical Center (074-010)', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '20010', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'MedStar Health Research Institute', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '20422', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'Washington DC Veterans Affairs Medical Center', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '21201', 'city': 'Baltimore', 'state': 'Maryland', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'University of Maryland Medical System', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '48202', 'city': 'Detroit', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Washington DC ICC', 'role': 'CONTACT', 'email': 'otacwdc@insight-trials.org'}, {'name': 'Indira Brar, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Henry Ford Health System Site (014-001)', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '49525', 'city': 'Grand Rapids', 'state': 'Michigan', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'Infusion Associates', 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'zip': '10003', 'city': 'New York', 'state': 'New York', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'Mount Sinai Beth Israel Hospital', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10029', 'city': 'New York', 'state': 'New York', 'status': 'TERMINATED', 'country': 'United States', 'facility': 'Icahn School of Medicine at Mount Sinai', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '44195', 'city': 'Cleveland', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Hennepin ICC', 'role': 'CONTACT', 'email': 'otachenn@insight-trials.org'}], 'facility': 'Cleveland Clinic Foundation (Site 207-001)', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '17033', 'city': 'Hershey', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Hennepin ICC', 'role': 'CONTACT', 'email': 'otachenn@insight-trials.org'}], 'facility': 'Penn State Health Milton S. Hershey Medical Center (209-002)', 'geoPoint': {'lat': 40.28592, 'lon': -76.65025}}, {'zip': '79601', 'city': 'Abilene', 'state': 'Texas', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'Hendrick Medical Center', 'geoPoint': {'lat': 32.44874, 'lon': -99.73314}}, {'zip': '78404', 'city': 'Corpus Christi', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Hennepin ICC', 'role': 'CONTACT', 'email': 'otachenn@insight-trials.org'}, {'name': 'Srikanth Ramachandruni, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHRISTUS Spohn Shoreline Hospital', 'geoPoint': {'lat': 27.80058, 'lon': -97.39638}}, {'zip': '75390', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Washington DC ICC', 'role': 'CONTACT', 'email': 'otacwdc@insight-trials.org'}, {'name': 'Mamta Jain, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UT Southwestern Medical Center', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '84107', 'city': 'Murray', 'state': 'Utah', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Nashville ICC', 'role': 'CONTACT', 'email': 'otacnash@insight-trials.org'}], 'facility': 'Intermountain Medical Center (211-001)', 'geoPoint': {'lat': 40.66689, 'lon': -111.88799}}, {'zip': '22908', 'city': 'Charlottesville', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Hennepin ICC', 'role': 'CONTACT', 'email': 'otachenn@insight-trials.org'}, {'name': 'Jeffrey Sturek', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UVA Health System, University Hospital (Site 210-003)', 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}, {'zip': '24015', 'city': 'Roanoke', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Hennepin ICC', 'role': 'CONTACT', 'email': 'otachenn@insight-trials.org'}, {'name': 'Lana Wahid', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Carilion Medical Center (Site 080-018)', 'geoPoint': {'lat': 37.27097, 'lon': -79.94143}}, {'zip': '24153', 'city': 'Salem', 'state': 'Virginia', 'status': 'TERMINATED', 'country': 'United States', 'facility': 'Salem VA Medical Center (074-014)', 'geoPoint': {'lat': 37.29347, 'lon': -80.05476}}, {'zip': '98122', 'city': 'Seattle', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Washington ICC', 'role': 'CONTACT', 'email': 'otacwdc@insight-trials.org'}, {'name': 'Jason Goldman, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Swedish Hospital First Hill', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': 'B1900AVG', 'city': 'La Plata', 'state': 'Buenos Aires', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Sydney ICC', 'role': 'CONTACT', 'email': 'otacsyd@insight-trials.org'}, {'name': 'Analia Mykietiuk, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Instituto Medico Platense', 'geoPoint': {'lat': -34.92126, 'lon': -57.95442}}, {'zip': 'B7600FYK', 'city': 'Mar del Plata', 'state': 'Buenos Aires', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Sydney ICC', 'role': 'CONTACT', 'email': 'otacsyd@insight-trials.org'}, {'name': 'Alejandro Ferro, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centro de Investigaciones Medicas de Mar del Plata (Site 611-031)', 'geoPoint': {'lat': -38.00042, 'lon': -57.5562}}, {'zip': 'R8336', 'city': 'Villa Regina', 'state': 'Río Negro Province', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Sydney ICC', 'role': 'CONTACT', 'email': 'strivesyd@insight-trials.org'}], 'facility': 'Clínica Central S.A. (611-028)', 'geoPoint': {'lat': -39.09631, 'lon': -67.08374}}, {'zip': 'C1221ADC', 'city': 'Buenos Aires', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Sydney ICC', 'role': 'CONTACT', 'email': 'otacsyd@insight-trials.org'}, {'name': 'Marcelo Horacio Losso, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital General de Agudos JM Ramos Mejia', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '2010', 'city': 'Sydney', 'state': 'New South Wales', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Sydney ICC', 'role': 'CONTACT', 'email': 'otacsyd@insight-trials.org'}, {'name': 'Gail Matthews, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "St. Vincent's Hospital", 'geoPoint': {'lat': -33.86785, 'lon': 151.20732}}, {'zip': '5000', 'city': 'Odense', 'state': 'C', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'Copenhagen ICC', 'role': 'CONTACT', 'email': 'otaccph@insight-trials.org'}, {'name': 'Isik Somuncu Johansen, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Odense University Hospital', 'geoPoint': {'lat': 55.39594, 'lon': 10.38831}}, {'zip': '8200', 'city': 'Aarhus', 'state': 'N', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'Copenhagen ICC', 'role': 'CONTACT', 'email': 'otaccph@insight-trials.org'}, {'name': 'Lars Østergaard, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Aarhus Universitetshospital, Skejby', 'geoPoint': {'lat': 56.15674, 'lon': 10.21076}}, {'zip': '9000', 'city': 'Aalborg', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'Copenhagen ICC', 'role': 'CONTACT', 'email': 'otaccph@insight-trials.org'}, {'name': 'Henrik Nielsen, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Department of Infectious Diseases', 'geoPoint': {'lat': 57.048, 'lon': 9.9187}}, {'zip': '2100', 'city': 'Copenhagen', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'Copenhagen ICC', 'role': 'CONTACT', 'email': 'otaccph@insight-trials.org'}, {'name': 'Marie Helleberg, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Rigshospitalet, CHIP', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}, {'zip': '2400', 'city': 'Copenhagen', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'Copenhagen ICC', 'role': 'CONTACT', 'email': 'otaccph@insight-trials.org'}, {'name': 'Daria Podlekareva, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Bispebjerg Hospital', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}, {'zip': '2900', 'city': 'Hellerup', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'Copenhagen ICC', 'role': 'CONTACT', 'email': 'otaccph@insight-trials.org'}, {'name': 'Jens Ulrik Stæhr Jensen, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Herlev/Gentofte Hospital', 'geoPoint': {'lat': 55.73204, 'lon': 12.57093}}, {'zip': '2650', 'city': 'Hvidovre', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'Copenhagen ICC', 'role': 'CONTACT', 'email': 'otaccph@insight-trials.org'}, {'name': 'Thomas Benfield, MN', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hvidovre University Hospital, Department of Infectious Diseases', 'geoPoint': {'lat': 55.64297, 'lon': 12.47708}}, {'zip': '6000', 'city': 'Kolding', 'status': 'RECRUITING', 'country': 'Denmark', 'contacts': [{'name': 'Copenhagen ICC', 'role': 'CONTACT', 'email': 'otaccph@insight-trials.org'}, {'name': 'Birgit Røge, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Kolding Sygehus', 'geoPoint': {'lat': 55.4904, 'lon': 9.47216}}, {'zip': '10676', 'city': 'Athens', 'state': 'Attica', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'London ICC', 'role': 'CONTACT', 'email': 'otaclon@insight-trials.org'}, {'name': 'Ioannis Kalomenidis, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Dept of Critical Care and Pulmonary Medicine, Evangelismos General Hospital', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '11527', 'city': 'Athens', 'state': 'Attica', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'London ICC', 'role': 'CONTACT', 'email': 'otaclon@insight-trials.org'}, {'name': 'Garyfallia Poulakou, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': '3rd Dept of Medicine, Medical School', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '11527', 'city': 'Athens', 'state': 'Attica', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'London ICC', 'role': 'CONTACT', 'email': 'otaclon@insight-trials.org'}, {'name': 'Nikolaos Sypsas, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Laiko Athens General Hospital', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '11528', 'city': 'Athens', 'state': 'Attica', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'London ICC', 'role': 'CONTACT', 'email': 'otaclon@insight-trials.org'}, {'name': 'Eleni Korompoki, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Department of Clinical Therapeutics of Alexandra Hospital', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '12462', 'city': 'Athens', 'state': 'Attica', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'London ICC', 'role': 'CONTACT', 'email': 'otaclon@insight-trials.org'}, {'name': 'Anastasia Antoniadou, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': '4th Department of Internal Medicine', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '342005', 'city': 'Jodhpur', 'state': 'Rajasthan', 'status': 'WITHDRAWN', 'country': 'India', 'facility': 'All India Institute of Medical Sciences (AIIMS)', 'geoPoint': {'lat': 26.26841, 'lon': 73.00594}}, {'zip': '160012', 'city': 'Chandigarh', 'status': 'WITHDRAWN', 'country': 'India', 'facility': 'Postgraduate Institute of Medical Education and Research (PGIMER)', 'geoPoint': {'lat': 30.73629, 'lon': 76.7884}}, {'zip': '14080', 'city': 'Mexico City', 'state': 'Mexico City', 'status': 'RECRUITING', 'country': 'Mexico', 'contacts': [{'name': 'Washington ICC', 'role': 'CONTACT', 'email': 'otacwdc@insight-trials.org'}, {'name': 'Juan Pablo Ramirez Hinojosa, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital General Dr. Manuel Gea Gonzáles', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'zip': '14080', 'city': 'Mexico City', 'state': 'Mexico City', 'status': 'RECRUITING', 'country': 'Mexico', 'contacts': [{'name': 'Washington ICC', 'role': 'CONTACT', 'email': 'otacwdc@insight-trials.org'}, {'name': 'Sandra Rajme-Lopez, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'zip': '14080', 'city': 'Mexico City', 'state': 'Mexico City', 'status': 'RECRUITING', 'country': 'Mexico', 'contacts': [{'name': 'Washington ICC', 'role': 'CONTACT', 'email': 'otacwdc@insight-trials.org'}, {'name': 'Pamela Garciadiego Fossas, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Instituto Nacional de Enfermedades Respiratorias Ismael Cosió Villegas', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'zip': '64060', 'city': 'Monterrey', 'state': 'Nuevo León', 'status': 'WITHDRAWN', 'country': 'Mexico', 'facility': 'CHRISTUS Centro de Excelencia en Investigacion (Obispado)', 'geoPoint': {'lat': 25.68435, 'lon': -100.31721}}, {'zip': '68050', 'city': 'Oaxaca City', 'state': 'OA', 'status': 'RECRUITING', 'country': 'Mexico', 'contacts': [{'name': 'Washington ICC', 'role': 'CONTACT', 'email': 'otacwdc@insight-trials.org'}, {'name': 'Yuri Alfonso Roldán Aragón, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital General Dr. Aurelio Valdivieso', 'geoPoint': {'lat': 17.06025, 'lon': -96.72544}}, {'zip': '15012', 'city': 'Lima', 'status': 'RECRUITING', 'country': 'Peru', 'contacts': [{'name': 'Washington ICC', 'role': 'CONTACT', 'email': 'strivewdc@insight-trials.org'}], 'facility': 'Unidad de Ensayos Clinicos Socios En Salud Sucursal Perú (651-009)', 'geoPoint': {'lat': -12.04318, 'lon': -77.02824}}, {'zip': '08916', 'city': 'Badalona', 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Copenhagen ICC', 'role': 'CONTACT', 'email': 'otaccph@insight-trials.org'}, {'name': 'Roger Paredes Deiros, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Universitari Germans Trias i Pujol', 'geoPoint': {'lat': 41.45004, 'lon': 2.24741}}, {'zip': '08860', 'city': 'Castelldefels', 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Copenhagen ICC', 'role': 'CONTACT', 'email': 'otaccph@insight-trials.org'}, {'name': 'Núria Freixenet, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CAP Can Bou', 'geoPoint': {'lat': 41.27794, 'lon': 1.97033}}, {'zip': '08303', 'city': 'Mataró', 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Copenhagen ICC', 'role': 'CONTACT', 'email': 'otaccph@insight-trials.org'}, {'name': 'Pere Torán-Monserrat, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CAP El Maresme', 'geoPoint': {'lat': 41.54211, 'lon': 2.4445}}, {'zip': '08757', 'city': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Copenhagen ICC', 'role': 'CONTACT', 'email': 'otaccph@insight-trials.org'}, {'name': 'Verónica Beatriz Gómez Martínez', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CAP Corbera', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '10700', 'city': 'Bangkok Noi', 'state': 'Bangkok', 'status': 'RECRUITING', 'country': 'Thailand', 'contacts': [{'name': 'Sydney ICC', 'role': 'CONTACT', 'email': 'otacsyd@insight-trials.org'}, {'name': 'Methee Chayakulkeeree', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Siriraj Hospital (Site 613-002)', 'geoPoint': {'lat': 13.76266, 'lon': 100.47798}}, {'zip': '10330', 'city': 'Pathum Wan', 'state': 'Bangkok', 'status': 'RECRUITING', 'country': 'Thailand', 'contacts': [{'name': 'Sydney ICC', 'role': 'CONTACT', 'email': 'otacsyd@insight-trials.org'}, {'name': 'Anchalee Avihingsanon, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Chulalongkorn University and The HIV-NAT', 'geoPoint': {'lat': 13.73649, 'lon': 100.5239}}, {'zip': '40002', 'city': 'Khon Kaen', 'status': 'RECRUITING', 'country': 'Thailand', 'contacts': [{'name': 'Sydney ICC', 'role': 'CONTACT', 'email': 'strivesyd@insight-trials.org'}, {'name': 'Piroon Mootsikapun', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Khon Kaen University, Srinagarind Hospital (Site 613-003)', 'geoPoint': {'lat': 16.44671, 'lon': 102.833}}, {'zip': '11000', 'city': 'Nonthaburi', 'status': 'RECRUITING', 'country': 'Thailand', 'contacts': [{'name': 'Sydney ICC', 'role': 'CONTACT', 'email': 'otacsyd@insight-trials.org'}], 'facility': 'Bamrasnaradura Infections Diseases Institute (613-007)', 'geoPoint': {'lat': 13.86075, 'lon': 100.51477}}, {'city': 'Entebbe', 'status': 'RECRUITING', 'country': 'Uganda', 'contacts': [{'name': 'London ICC', 'role': 'CONTACT', 'email': 'otaclon@insight-trials.org'}, {'name': 'Joseph Lutaakome, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'MRC/UVRI & LSHTM Uganda Research Unit', 'geoPoint': {'lat': 0.05621, 'lon': 32.47949}}, {'city': 'Kampala', 'status': 'RECRUITING', 'country': 'Uganda', 'contacts': [{'name': 'London ICC', 'role': 'CONTACT', 'email': 'otaclon@insight-trials.org'}, {'name': 'Henry Mugerwa, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Joint Clinical Research Center (JCRC)', 'geoPoint': {'lat': 0.31628, 'lon': 32.58219}}, {'city': 'Kampala', 'status': 'RECRUITING', 'country': 'Uganda', 'contacts': [{'name': 'London ICC', 'role': 'CONTACT', 'email': 'otaclon@insight-trials.org'}, {'name': 'Francis Kiweewa', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Makerere University Lung Institute (Site 634-604)', 'geoPoint': {'lat': 0.31628, 'lon': 32.58219}}, {'city': 'Kampala', 'status': 'RECRUITING', 'country': 'Uganda', 'contacts': [{'name': 'London ICC', 'role': 'CONTACT', 'email': 'otaclon@insight-trials.org'}, {'name': 'Joseph Lutaakome, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'St. Francis Hospital, Nsambya', 'geoPoint': {'lat': 0.31628, 'lon': 32.58219}}, {'city': 'Lira', 'status': 'RECRUITING', 'country': 'Uganda', 'contacts': [{'name': 'London ICC', 'role': 'CONTACT', 'email': 'otaclon@insight-trials.org'}, {'name': 'Francis Kiweewa', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Lira Regional Referral Hospital', 'geoPoint': {'lat': 2.2499, 'lon': 32.89985}}, {'city': 'Masaka', 'status': 'RECRUITING', 'country': 'Uganda', 'contacts': [{'name': 'London ICC', 'role': 'CONTACT', 'email': 'otaclon@insight-trials.org'}, {'name': 'Joseph Lutaakome, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Masaka Regional Referral Hospital', 'geoPoint': {'lat': -0.33379, 'lon': 31.73409}}, {'zip': '76018', 'city': 'Ivano-Frankivsk', 'status': 'RECRUITING', 'country': 'Ukraine', 'contacts': [{'name': 'Copenhagen ICC', 'role': 'CONTACT', 'email': 'otaccph@insight-trials.org'}], 'facility': 'Central City Clinical Hospital of Ivano-Frankivsk City Council', 'geoPoint': {'lat': 48.92312, 'lon': 24.71248}}, {'zip': 'WC1E 6JB', 'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'London ICC', 'role': 'CONTACT', 'email': 'otaclon@insight-trials.org'}, {'name': 'Robert Miller', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University College London Hospitals', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'NE1 4LP', 'city': 'Newcastle upon Tyne', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'London ICC', 'role': 'CONTACT', 'email': 'otaclon@insight-trials.org'}, {'name': 'David Ashley Price, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Royal Victoria Infirmary', 'geoPoint': {'lat': 54.97328, 'lon': -1.61396}}], 'centralContacts': [{'name': 'Gary Collins', 'role': 'CONTACT', 'email': 'gary-c@ccbr.umn.edu', 'phone': '612-626-9006'}], 'overallOfficials': [{'name': 'Cavan Reilly, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Minnesota'}]}, 'ipdSharingStatementModule': {'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'], 'ipdSharing': 'YES', 'description': 'A public data set will be made available at the end of the trial.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Minnesota', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute of Allergy and Infectious Diseases (NIAID)', 'class': 'NIH'}, {'name': 'National Institutes of Health (NIH)', 'class': 'NIH'}, {'name': 'International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)', 'class': 'NETWORK'}], 'responsibleParty': {'type': 'SPONSOR'}}}}